Why a wave of lawsuits has put Medpace Holdings (MEDP) in the spotlight

Recent securities class actions against Medpace Holdings (MEDP) allege false and misleading statements about book to bill guidance, backlog cancellations, and business prospects, with investors pointing to fourth quarter 2025 results as the turning point.

Medpace’s share price has recently been volatile, with a 7 day share price return of 4.22% and a 30 day share price return of 5.42%. However, year to date the share price is down 24.21%, even as the 1 year total shareholder return sits at 46.77%, suggesting momentum has cooled after a stronger run over recent years.

If these legal headlines have you reassessing your exposure to healthcare, it might be worth widening your search with a curated set of 34 healthcare AI stocks

With Medpace trading close to the average analyst price target yet flagged with an intrinsic discount of about 32%, investors are left with a key question: is the recent pullback a genuine opportunity, or is the stock already pricing in future growth?

Most Popular Narrative: 13.5% Undervalued

With Medpace last closing at $432.80 against a widely followed fair value estimate of about $500.08, the core question is how the underlying earnings and cash flow story supports that gap.

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive. This could result in lower underlying revenue and EBITDA growth once this project mix normalizes.

Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside. If the improved funding environment or lower cancellations were to reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.

Want to understand why this valuation still lands above the current share price? The narrative rests on a specific earnings glide path, firm margin assumptions, and a future P/E that implies a tighter gap to sector leaders. Curious which revenue profile and profitability mix underpin that fair value and how buybacks fit into the equation?

Result: Fair Value of $500.08 (UNDERVALUED)

However, the story can change quickly if biotech funding weakens again or faster burning contracts roll off sooner than expected, pressuring backlog and earnings visibility.

Next Steps

Given this mixed sentiment, do not wait for the next headline to make up your mind. Review the upside factors yourself with the 3 key rewards

Looking for more investment ideas?

If you stop with Medpace, you risk missing other stocks that might suit your goals, so take a few minutes to scan a wider opportunity set.

• Spot potential bargains quickly by checking out 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Prioritize resilience by reviewing 67 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by using the screener containing 21 high quality undiscovered gems to surface underfollowed stocks with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.